Creavo Medical Technologies (Creavo) has announced the enrolment of the last patient in a study led by the cardiology team at the South Warwickshire NHS Foundation Trust.
The study will assess if Creavo’s magnetocardiography (MCG) device can differentiate between the hearts of those who have previously suffered from a cardiac event, such as a myocardial infarction, and the hearts of healthy (non-ischaemic) patients.
Approximately 100 patients have been enrolled throughout the study (50 healthy and 50 post-cardiac event) and the results are intended to determine if MCG can detect damage in the hearts of those patients with a recently confirmed MI.
Dr Roger Beadle, Consultant Cardiologist at the University of Warwick, commented: “The research team at South Warwickshire NHS Foundation are excited to be a part of this MCG project. Bringing a new technology into a hospital is a great opportunity. “The use of MCG in the field of acute coronary syndromes is well documented but the possibilities for this technology extend far beyond that. We hope that this piece of research will be our first step in exploring this.”
Steve Parker, Chief Executive Officer of Creavo Medical Technologies, added:
“While we continue to carry out research with MCG in the emergency department, this is our initial step into how Creavo’s unique MCG technology adds value and can be utilised in the cardiology setting. The aim is to provide physicians with an accurate ischaemic condition of the heart, helping them decide on the most appropriate care pathway for the patient.
“We are delighted to be working alongside Dr Beadle and his team for this study and thank them for their support. We look forward to working with further patients, and to obtaining results which are expected shortly.”
News & Analysis